Comment from EHE Foundation

Summary: The EHE Foundation, an advocacy organization for patients with an ultra-rare cancer, supports the revised draft guidance because it provides a realistic pathway for developing treatments for rare diseases with small patient populations. They request further clarification on evidentiary bars for natural history data, the scope of mechanistic-evidence pathways for gene-fusion-driven cancers, and dedicated engagement mechanisms for small sponsors.